Research progress on potential targets of liposarcoma / 实用肿瘤学杂志
Practical Oncology Journal
; (6): 82-86, 2019.
Article
em Zh
| WPRIM
| ID: wpr-752818
Biblioteca responsável:
WPRO
ABSTRACT
Liposarcoma(LPS)is the most common type of soft-tissue sarcoma(STS). The current treatment methods are still based on complete surgical resection. Radiotherapy and chemotherapy as adjuvant treatment or distant metastasis,and the main treat-ment of unresectable liposarcoma have limited efficacy,have not widely recognized. With the extensive and in-depth of LPS molecular targeted therapy,the research achievements in this area are remarkable. Emerging targets for LPS include receptors such as tyrosine ki-nase receptor AXL,fibroblast growth factor receptor(FGFR),insulin-like growth factor-1 receptor(IGF-1R),nuclear export re-ceptor XPO1(Exportin-1),and proteins/enzymes such as heat shock protein 90( Hsp90),bispecific tyrosine( Y) phosphorylation-regulated kinase 1B( DYRK1B) and signal pathways such as SRC/FAK/RHO/ROCK have shown good prospects for anti-LPS in preclinical studies. The research progress in the aspects is summarized as follows.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Practical Oncology Journal
Ano de publicação:
2019
Tipo de documento:
Article